Every material Form 8-K Charles River Laboratories has filed with the SEC since November 06, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Charles River Laboratories International reported third-quarter 2026 revenue of $982.7 million and increased its full-year guidance for revenue and non-GAAP earnings per share. The results were driven by a 4.7% increase in organic revenue and a lower tax rate, alongside a significant benefit from the reversal of acquired tax reserves.
Charles River reported second-quarter 2026 revenue of $1.00 billion, down 2.7% from a year earlier, and non-GAAP earnings per share of $3.02, down 3.2%. A $63.7 million loss on the CDMO and Cell Solutions divestiture produced a GAAP net loss of $(1.5) million, or $(0.03) per diluted share. The company raised its 2026 non-GAAP EPS guidance but lowered its GAAP EPS guidance.
Q2 revenue $1.00 billion, down 2.7% from $1.03 billion; organic revenue up 0.1%
GAAP net loss $(1.5) million, or $(0.03) per diluted share, vs. net income of $52.3 million, or $1.06, a year earlier
Non-GAAP EPS $3.02, down 3.2% from $3.12; non-GAAP operating margin 20.5% vs. 22.1%
2026 non-GAAP EPS guidance raised to $11.15–$11.45 from $10.80–$11.30; GAAP EPS guidance cut to $3.05–$3.35 from $5.35–$5.85
At its May 5, 2026 annual meeting, Charles River Laboratories shareholders elected all 12 director nominees, approved a new 2026 Long-Term Incentive Plan, approved executive pay on an advisory basis, and ratified PricewaterhouseCoopers LLP as auditor for fiscal 2026. The votes are routine annual-meeting matters with no change in financial results or guidance reported in this filing.
All 12 directors were elected to serve until the 2027 annual meeting; each received more votes for than against.
The 2026 Long-Term Incentive Plan was approved with 41,523,179 votes for and 2,561,994 against.
Advisory say-on-pay was approved with 41,356,139 votes for and 2,716,251 against.
PricewaterhouseCoopers LLP was ratified as independent auditor for fiscal 2026 with 43,646,371 votes for.
Charles River reported first-quarter 2026 revenue of $995.8 million, up 1.2% from a year earlier but down 1.5% on an organic basis. The GAAP net loss was $14.8 million, or $0.30 per diluted share, mainly due to a $118.0 million loss on assets held for sale tied to the CDMO and Cell Solutions divestiture, which closed May 6, 2026. Non-GAAP EPS was $2.06, down 12.0%, and the company reaffirmed its 2026 organic revenue and non-GAAP EPS guidance while lowering its reported revenue outlook by about 50 basis points.
Revenue was $995.8 million, up 1.2%; organic revenue declined 1.5%.
GAAP net loss of $14.8 million, or $0.30 per diluted share, versus net income of $25.5 million, or $0.50, in Q1 2025.
Non-GAAP diluted EPS was $2.06, down 12.0% from $2.34 a year earlier.
2026 non-GAAP EPS guidance of $10.80 to $11.30 was reaffirmed; reported revenue outlook was cut by about 50 basis points on foreign exchange assumptions.
Charles River Laboratories appointed Glenn Coleman as Corporate Executive Vice President and Chief Financial Officer, with a tentative start date of April 6, 2026. He succeeds interim CFO Michael G. Knell, who will remain as Chief Accounting Officer.
Coleman, 58, is currently CFO and Chief Administrative Officer of Premier, Inc. and previously served as CFO of DENTSPLY SIRONA and Integra Life Sciences.
Offer letter sets a base salary of $800,000 and a 2026 target bonus of 85% of base salary, pro-rated to his hire date.
Coleman receives a 2026 equity award with a grant value of $3,000,000 and a one-time new hire equity award of $3,500,000, plus a one-time cash award of $1,875,000.
Charles River Laboratories reported fourth-quarter 2025 revenue of $994.2 million, down 0.8% from a year earlier, and a GAAP net loss of $(276.6) million, or $(5.62) per diluted share, driven by non-cash impairments. Non-GAAP earnings per share fell 10.2% to $2.39, and the company guided 2026 non-GAAP earnings per share to $10.70 to $11.20, which it said would be an increase of about 4% to 9%.
Q4 2025 revenue was $994.2 million, down 0.8% from $1,002.5 million; organic revenue declined 2.6%.
Q4 GAAP net loss was $(276.6) million, or $(5.62) per diluted share, including $211.0 million of intangible asset impairments and a $165.0 million goodwill impairment.
Q4 non-GAAP diluted EPS was $2.39, down 10.2% from $2.66; non-GAAP operating margin fell to 18.1% from 19.9%.
2026 guidance: non-GAAP EPS of $10.70 to $11.20 and GAAP EPS of $6.30 to $6.80; guidance excludes planned divestitures of about 7% of annual revenue.
Charles River Laboratories said at a J.P. Morgan conference that demand for its Discovery and Safety Assessment business improved through the second half of 2025, with a preliminary fourth-quarter book-to-bill of about 1.1x. The company also signed an agreement to buy K.F. (Cambodia) Ltd. for about $510 million and is exercising an option to buy the remaining 79% of PathoQuest SAS for about $60 million, which it expects to help non-GAAP earnings per share.
Preliminary DSA net book-to-bill of approximately 1.1x in Q4 2025; the company says the figure may change once audited 2025 results are complete
K.F. (Cambodia) Ltd. purchase price about $510 million, expected to close early in Q1 2026, with accretion of about $0.25 to 2026 and $0.60 to 2027 non-GAAP EPS
PathoQuest SAS remaining 79% stake for €51.6 million (about $60 million), expected to close by end of Q1 2026
2026 outlook: top end of organic revenue growth ranges expected to be at least flat; incremental cost savings above $100 million
Charles River Laboratories announced that Chairman and CEO James Foster will step down, and Chief Operating Officer Birgit Girshick will become CEO, both effective May 5, 2026. Foster will remain a non-executive director, and Lead Independent Director Martin Mackay is expected to become Board Chair on the same date.
Birgit Girshick, current COO, to become CEO effective May 5, 2026, and to join the Board at the 2026 Annual Meeting
Base salary set at $1,200,000 effective February 1, 2026; initial equity grant with target value of $9,000,000
Severance if terminated without cause or for good reason before first anniversary of a change in control: three times salary plus target bonus
Charles River reported third-quarter 2025 revenue of $1.00 billion, down 0.5% from $1.01 billion a year earlier, and non-GAAP diluted EPS of $2.43, down 6.2% from $2.59. GAAP diluted EPS was $1.10, down from $1.33, mainly due to a $0.33 per share loss on venture capital and strategic investments. The company narrowed its 2025 outlook to the middle and upper ends of its prior revenue and EPS ranges, with non-GAAP EPS now estimated at $10.10 to $10.30.
Q3 revenue was $1.00 billion, down 0.5%; organic revenue fell 1.6%.
Non-GAAP diluted EPS was $2.43, down 6.2% from $2.59; GAAP diluted EPS was $1.10 versus $1.33.
2025 non-GAAP EPS estimate is now $10.10 to $10.30, compared with $9.90 to $10.30 previously.
RMS segment revenue rose 7.9% to $213.5 million, while DSA revenue fell 2.3% to $600.7 million.
Chief Financial Officer Flavia H. Pease will resign effective September 29, 2025, to pursue another opportunity, and Michael G. Knell, the Chief Accounting Officer, will serve as interim CFO until a permanent successor is named. The company said her decision was not the result of any disagreement over financial statements, internal controls, operations, policies or practices, and it reaffirmed its 2025 revenue and non-GAAP earnings per share guidance first provided on August 6, 2025.
Flavia H. Pease resigns as CFO effective September 29, 2025, to pursue another opportunity
Michael G. Knell, age 49, joined the company in April 2017 and will serve as interim CFO, effective upon Pease's departure
The company has commenced a comprehensive search for a permanent CFO; Knell's compensation terms were not determined as of the filing date
2025 revenue and non-GAAP EPS guidance, previously provided August 6, 2025, was reaffirmed
Charles River reported second-quarter 2025 revenue of $1.03 billion, up 0.6% as reported but down 0.5% organically, and non-GAAP earnings per share of $3.12, up 11.4%. GAAP earnings per share fell to $1.06 from $1.74, mainly due to accelerated amortization and restructuring and legal costs. The company raised its full-year non-GAAP earnings per share guidance but lowered its GAAP earnings per share guidance.
Q2 revenue was $1,032.1 million, up 0.6% reported and down 0.5% organic; DSA segment organic revenue fell 2.4%.
Q2 GAAP net income available to common shareholders was $52.3 million, or $1.06 per share, versus $90.0 million, or $1.74 per diluted share, a year earlier.
2025 non-GAAP EPS guidance was raised to $9.90-$10.30 from $9.30-$9.80; GAAP EPS guidance was lowered to $4.25-$4.65 from $4.35-$4.85.
The company said the U.S. Department of Justice had closed the grand jury and parallel civil investigations into its NHP shipments.
Charles River Laboratories amended CEO James Foster's employment agreement on May 20, 2025, extending his term by one year to February 12, 2027, with all other terms unchanged. At the same meeting, shareholders re-elected seven directors, approved executive pay on an advisory basis, ratified PricewaterhouseCoopers as auditor, and rejected a PETA-submitted proposal on non-human primates.
Foster employment term extended one year to February 12, 2027; other terms unchanged
Seven directors elected to serve until the 2026 Annual Meeting; Steven Barg, Mark Enyedy, Abraham Ceesay and Paul Graves appointed to the Board
Advisory vote on executive compensation: 40,218,870 for and 1,432,240 against
PETA proposal on non-human primates not approved: 3,457,547 for and 38,051,509 against
Charles River Laboratories entered a Cooperation Agreement with activist investor Elliott Investment Management, which will add four new directors after the May 20, 2025 annual meeting and launch a comprehensive strategic review of the business. Four incumbent directors will not stand for re-election, and the board will be limited to 11 members while the agreement is in effect.
Steven Barg, Abe Ceesay, Mark Enyedy and Paul Graves join the board after the May 20, 2025 annual meeting, each for a term ending at the 2026 annual meeting.
Robert Bertolini, Deborah Kochevar, George Massaro and Richard Wallman will not stand for re-election at the 2025 annual meeting.
The Strategic Planning and Capital Allocation Committee will review the business and examine alternatives to enhance long-term stockholder value, then report to the full board.
The filing gives no financial results or guidance; the press release describes Elliott as the company's largest investor.
Charles River Laboratories reported first-quarter 2025 revenue of $984.2 million, down 2.7% from $1,011.6 million a year earlier, with GAAP diluted earnings per share of $0.50 versus $1.30. Non-GAAP diluted EPS rose 3.1% to $2.34, and the company raised its 2025 non-GAAP EPS guidance to $9.30 to $9.80 from $9.10 to $9.60, which matters to shareholders because revenue and GAAP profit declined while the outlook moved higher.
Q1 2025 revenue was $984.2 million, down 2.7% from $1,011.6 million; organic revenue fell 1.8%.
GAAP diluted EPS was $0.50 versus $1.30 in Q1 2024; non-GAAP diluted EPS was $2.34 versus $2.27.
2025 non-GAAP EPS guidance raised to $9.30 to $9.80 from $9.10 to $9.60; reported revenue guidance is now (5.5)% to (3.5)%.
The company repurchased $350 million of common stock in Q1 and had $549.3 million remaining on its $1.0 billion authorization as of March 29, 2025.
Charles River Laboratories reported fourth-quarter 2024 revenue of $1.00 billion, down 1.1%, and a GAAP loss of $4.22 per share after a $215.0 million goodwill impairment tied to its Biologics Solutions unit. Non-GAAP EPS rose 8.1% to $2.66 in the quarter, but full-year 2024 non-GAAP EPS fell 3.3% to $10.32, and the company guided to lower 2025 revenue and non-GAAP EPS of $9.10 to $9.60 while planning about $350 million in stock repurchases.
Q4 2024 revenue was $1.00 billion, down 1.1% from $1.01 billion; organic revenue declined 1.8%
Q4 GAAP loss per share was $(4.22), versus $3.62 diluted EPS a year earlier; the goodwill impairment accounted for $4.20 per share
2025 guidance: reported revenue decline of 7.0% to 4.5%; non-GAAP EPS of $9.10 to $9.60 versus $10.32 in 2024
Company plans to repurchase approximately $350 million of common stock in 2025
Charles River reported third-quarter 2024 revenue of $1.01 billion, down 1.6% from a year earlier, with GAAP diluted EPS of $1.33, down 21.3%, and non-GAAP diluted EPS of $2.59, down 4.8%. The company raised its 2024 non-GAAP EPS guidance to $10.10-$10.30 from $9.90-$10.20 but cut its GAAP EPS guidance to $5.30-$5.50 from $5.65-$5.95, citing higher restructuring charges.
Q3 revenue $1.01 billion vs. $1.03 billion in Q3 2023; organic revenue declined 2.7%
GAAP diluted EPS $1.33 vs. $1.69; non-GAAP diluted EPS $2.59 vs. $2.72
2024 non-GAAP EPS guidance raised to $10.10-$10.30; GAAP EPS guidance cut to $5.30-$5.50
Board approved a $1.0 billion buyback on August 2, 2024; $899.3 million remained as of September 28, 2024
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Charles River Laboratories filing is on SEC EDGAR ↗. 8-K briefs of other companies →